BACKProbiotic Compositions for Treating and Preventing Colorectal Cancer
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 11 November 2021]
We are inviting expressions of interest (EoI) for commercializing “Probiotic Compositions for Treating and Preventing Colorectal Cancer” technology. The innovation is developed by Professor YU Jun, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 21/MED/1037).
The Technology
The invention disclosed three probiotics, and one probiotic cocktail for treating and preventing CRC. This invention will bring the consideration and practice of prevention of CRC by probiotic bacteria to the primary healthcare scene by supporting their prevention effectiveness of CRC in an evidence-based approach.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Probiotic Compositions for Treating and Preventing Colorectal Cancer
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 11 November 2021]
We are inviting expressions of interest (EoI) for commercializing “Probiotic Compositions for Treating and Preventing Colorectal Cancer” technology. The innovation is developed by Professor YU Jun, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 21/MED/1037).
The Technology
The invention disclosed three probiotics, and one probiotic cocktail for treating and preventing CRC. This invention will bring the consideration and practice of prevention of CRC by probiotic bacteria to the primary healthcare scene by supporting their prevention effectiveness of CRC in an evidence-based approach.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Therapeutics
Erika Yuen
Office of Research and Knowledge Transfer Services
YU Jun
WU Ka Kei
LI Qing
N/A